Celmoleukin, identified by its CAS number 94218-72-1, is a synthetic compound that functions primarily as an immunomodulator. It is a fusion protein that combines elements of interleukin-2 (IL-2) with a specific targeting moiety, enhancing its ability to stimulate immune responses, particularly in the context of cancer therapy. Celmoleukin is designed to activate T-cells and natural killer (NK) cells, promoting their proliferation and cytotoxic activity against tumor cells. Its mechanism of action involves binding to IL-2 receptors on immune cells, leading to increased production of cytokines and enhanced immune surveillance. The compound is typically administered via injection and has been studied in various clinical settings, particularly for its potential in treating malignancies. As with many immunotherapeutic agents, its use may be associated with side effects related to immune activation, necessitating careful monitoring during treatment. Overall, Celmoleukin represents a promising approach in the field of cancer immunotherapy, leveraging the body's immune system to combat tumor growth.

Celmoleukin

94218-72-1:  Celmoleukina [INN-Spanish],  Celmoleukinum,  Celmoleukine [INN-French],  Celmoleukine,  UNII-644J6P3JM0,  Celmoleukina,  Celmoleukinum [INN-Latin],  Interleukin 2 (human clone pTIL2-21a, protein moiety), Celmoleukin [INN]

Please enquire for more information about rec IL-2 (human) including the price, delivery time and more detailed product information at the technical inquiry form on this page

CAS 94218-72-1: Celmoleukin

rec IL-2 (human)

Ref: 3D-FR110069